OR WAIT 15 SECS
Alizé Pharma 3 completed a €67 million Series A financing round led by LSP to boost its product portfolio in rare endocrine and metabolic diseases.
Alizé Pharma 3, a therapeutic peptides development company, has announced it completed a €67 million (more than US $74 million) Series A financing round led by LSP, including Novo Ventures, Kurma Partners, Orbimed, Pontifax, Partners Innovation Fund, and Innobio 2 (managed by Bpifrance), according to a July 31, 2019 press release. Existing shareholders, Sham Innovation Santé/Turenne Capital, Crédit Agricole Création, and TAB Consulting also participated.
The new capital will boost the company’s product portfolio in rare endocrine and metabolic diseases. The company portfolio currently contains two preclinical programs expected to reach clinical stage in 2020: AZP-3601, a parathyroid hormone for the treatment of hypoparathyroidism, and AZP-3404, a peptide that leverages the biology of insulin-like growth factor-binding protein-2 to treat syndromes of severe insulin resistance.
The company is planning to expand to Boston, MA, where it will open a subsidiary to implement global drug development capabilities.
“We are very pleased to receive support and financing from this group of high-quality, international investors who share our ambition to build a leading rare disease company specialized in endocrinology and metabolism,” said Thierry Abribat, founder and CEO of Alizé Pharma 3, in the press release. “We look forward to working with them to accelerate the structuring of the company and to advance our current product portfolio to ultimately provide new effective therapeutic approaches for rare endocrine and metabolic diseases with high unmet medical needs.”
Source: Alizé Pharma 3